Evgen Pharma plc
("Evgen" or "the
Company" or "the Group")
Positive update on SFX-01 on studies in
bowel cancer models
Further evidence of SFX-01 activity in
models of a major cancer
Alderley Park,
UK - 27 February 2024: Evgen
Pharma plc (AIM: EVG), the clinical stage drug development company
developing sulforaphane-based medicines for the treatment of
multiple diseases, announces that the laboratories of Professor
Grace Chen, Associate Professor Justin Colacino, and Professor
Duxin Sun at the University of Michigan, USA have observed activity
of SFX-01 in models of colon cancer.
The in
vitro and in vivo
studies, funded by the USA National Cancer Institute and the
University of Michigan will be generating data continuously
throughout the project.
According to one of the lead investigators,
Professor Chen
of the Division of
Hematology and Oncology, Department of Internal Medicine at the
University of Michigan Medical
School:
"We have shown preliminary signs of
anti-tumour activity of SFX-01 in organoids derived from human
tumours."
Dr Huw Jones,
CEO of Evgen Pharma said:
"These early
data from our collaborators in the USA show encouraging evidence of
activity of SFX-01 in another significant cancer. Colorectal or
bowel cancer is the third most common cancer worldwide accounting
for around one in ten of all cancer diagnoses and a cause of
significant morbidity and mortality. We look forward to continuing
to work with Prof Chen and colleagues to learn more about SFX-01 in
this setting."
-Ends-
Enquiries
Evgen
Pharma plc
Dr Huw Jones, CEO
Toni Hänninen, CFO
Dr Helen Kuhlman, CBO
|
+44 207 457 2020
enquiries@evgen.com
|
Cavendish Capital Markets (NOMAD and
Broker) Geoff Nash /
Teddy Whiley (Corporate Finance)
Nigel Birks (ECM)
|
+44 20 7220
0500
|
Instinctif Partners
Melanie Toyne-Sewell / Jack
Kincade
|
+44 207 457 2020
Evgen@Instinctif.com
|
About Evgen
Pharma plc
Evgen Pharma is a clinical stage drug
development company developing sulforaphane based medicines for the
treatment of multiple diseases. The Company's core technology is
Sulforadex®, a method for synthesising and stabilising the highly
biologically active compound sulforaphane and novel proprietary
analogues based on sulforaphane.
The Company's lead asset, SFX-01, is a patented
composition of synthetic sulforaphane and alpha-cyclodextrin and
has undergone clinical trials for oestrogen-positive (ER+)
metastatic breast cancer and recently a Phase 1b study of the
Company's new enteric coated tablet formulation. The FDA has
granted Orphan Drug status to SFX-01 in malignant glioma. SFX-01
will be investigated initially in this indication as an
investigator sponsored study in the Netherlands.
The Company also has a wide number of
collaborations with leading academic centres in the UK, Europe and
the US as part of the continuing strategy to build the scientific
data for the compound. Recently, Evgen completed an out-licensing
transaction with Stalicla SA, a Swiss specialist company in
neurodevelopmental disorders, commencing with autism spectrum
disorder. The deal, if successful, will generate milestone payments
of $160.5m and a double-digit royalty on sales.
The Company has its headquarters and registered
office at Alderley Park, Cheshire. It is listed on AIM in London
and trades under the ticker symbol EVG.
For further information, please
visit: www.evgen.com.